Rising Obesity Coupled with Increasing Blood Diseases Strengthen the Market Growth

The global thrombolysis market is anticipated to grow significantly at a CAGR of 5.9% during the forecast period. One of the primary factors contributing to the growth of the market is the rapidly rising prevalence of obesity across the globe owing to the changing lifestyle. Obesity is a complex disease involving an excessive amount of body fat. Obesity is one of the leading risk factors for premature death. It was linked to 4.7 million deaths globally in 2017. According to Our World In Data, 13% of adults in the world are obese. Obesity increases the risk of several debilitating, and deadly diseases, including diabetes, heart disease, and some cancers. Obese people have higher than normal blood pressure, low-density lipoprotein (LDL) cholesterol, triglycerides, and blood sugar, all of which contribute to heart disease. Arteries that become narrow can lead to a heart attack. Blood clots in narrow arteries can result in a stroke. In, addition according to Obesity Action Coalition, Every year, more than 795,000 people in the United States have a stroke. Stroke kills almost 130,000 Americans each year and is a leading cause of serious long-term disability. High blood pressure, high cholesterol, and smoking are major risk factors for stroke. Some key facts related to heart diseases according to CDC:

• About 659,000 people in the United States die from heart disease each year
• Coronary heart disease is the most common type of heart disease, killing 360,900 people in 2019
• Every year, about 805,000 people in the United States have a heart attack
• About 18.2 million adults age 20 and older have CAD

Browse the full report description “Global Thrombolysis Market Size, Share & Trends Analysis Report by Drug Types (Fibrin Specific Drug and Non-Fibrin Specific Drug), by Application (Deep Vein Thrombosis, Acute Ischemic Strokes, Pulmonary Embolism, Acute Myocardial, and Blocked Catheters), and by End-User (Hospitals and Ambulatory Surgical Centres)  Forecast Period (2022-2028)” at https://www.omrglobal.com/industry-reports/thrombolysis-market 

Market Coverage

• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028

Segment Covered-

• By Drug Types
• By Application
• By End-User

Regions Covered-

• North America
• Europe
• Asia-Pacific
• Rest of the World

Competitive Landscape- Genentech, Microbix , F.Hoffmann-La Roche Ltd., Livzon Diagnostics, Mochida Pharmaceutical Co., Ltd., and Others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment/region dominates the market in the base year?
• Which segment/region will project the fastest growth in the market?
• How has COVID-19 impacted the market?

oRecovery Timeline

oDeviation from the pre-COVID forecast

oMost affected region/segment

• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Thrombolysis Market– Segmentation

By Drug Types

• Fibrin Specific Drug
• Non- Fibrin Specific Drug

By Application

• Deep Vein Thrombosis
• Acute Ischemic Strokes
• Pulmonary Embolism
• Acute Myocardial
• Blocked Catheters

By End-User

• Hospitals
• Ambulatory Surgical Centres

Global ThrombolysisMarket by Region 

North America           

• US
• Canada

Europe

• Germany
• United Kingdom
• France
• Spain
• Italy
• Rest of Europe

Asia-Pacific    

• China
• Japan
• India
• Rest of Asia-Pacific

Rest of the World

• Middle East & Africa 
• Latin America 

To learn more about this report request a free sample copy @ https://www.omrglobal.com/request-sample/thrombolysis-market